Sakina SayahJeanne - Genfit Executive Science
| GNFT Stock | USD 4.21 0.06 1.41% |
Executive
Sakina SayahJeanne is Executive Science of Genfit
| Age | 52 |
| Address | Parc EurasantE, Loos, France, 59120 |
| Phone | 33 3 20 16 40 00 |
| Web | https://www.genfit.com |
Genfit Management Efficiency
The company has return on total asset (ROA) of 0.0651 % which means that it generated a profit of $0.0651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2591 %, meaning that it created $0.2591 on every $100 dollars invested by stockholders. Genfit's management efficiency ratios could be used to measure how well Genfit manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.21 in 2024. Total Current Liabilities is likely to drop to about 24.2 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 135.4 M in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Erin OBoyle | Rezolute | N/A | |
| Maria Dobek | Janux Therapeutics | 35 | |
| Terry Evans | Fennec Pharmaceuticals | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Arthur Hanson | Champions Oncology | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Ling Zhou | Adagene | N/A | |
| Marc MD | Edgewise Therapeutics | 67 | |
| MD MBA | Molecular Partners AG | N/A | |
| John MBA | Keros Therapeutics | N/A | |
| James Pennington | Janux Therapeutics | N/A | |
| Gopal MBBS | Rezolute | N/A | |
| Audrey SPHR | Harmony Biosciences Holdings | N/A | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Christian JD | Harmony Biosciences Holdings | N/A | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0651 |
Genfit Leadership Team
Elected by the shareholders, the Genfit's board of directors comprises two types of representatives: Genfit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genfit. The board's role is to monitor Genfit's management team and ensure that shareholders' interests are well served. Genfit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genfit's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefanie JD, Chief Affairs | ||
| Pascal Caisey, Chief Officer | ||
| Sakina SayahJeanne, Executive Science | ||
| Dean Hum, COO, Chief Scientific Officer, Member of the Management Board | ||
| Thomas Baetz, Chief Officer | ||
| Pr Staels, CoFounder Board | ||
| JeanChristophe Marcoux, Chief Officer | ||
| Meriam Kabbaj, Chief Officer | ||
| Pascal Prigent, Chief Officer | ||
| Laurent Lannoo, Corporate Affairs | ||
| JeanFrancois Mouney, Chairman of the Management Board, CEO | ||
| John Brozek, Executive Technology | ||
| Stefanie Magner, Chief Affairs | ||
| Emilie Desodt, Executive Resources |
Genfit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genfit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0651 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.51 % | ||||
| Current Valuation | 212.74 M | ||||
| Shares Outstanding | 49.91 M | ||||
| Shares Owned By Institutions | 0.25 % | ||||
| Number Of Shares Shorted | 62.94 K | ||||
| Price To Earning | 4.72 X | ||||
| Price To Book | 2.09 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genfit Stock Analysis
When running Genfit's price analysis, check to measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.